What is the current valuation of the US mycoplasma testing market?

The market valuation was $464.19 Million in 2024. Read More

What is the projected market size for the US mycoplasma testing market by 2035?

The market is projected to reach $1,529.59 Million by 2035. Read More

What is the expected CAGR for the US mycoplasma testing market during the forecast period 2025 - 2035?

The expected CAGR is 11.45% during the forecast period. Read More

Which test type segment is expected to show significant growth in the US mycoplasma testing market?

The Nucleic Acid Hybridization segment is projected to grow from $234.19 Million to $809.59 Million. Read More

What are the key applications driving the US mycoplasma testing market?

Key applications include Diagnostic Testing, which is expected to grow from $214.19 Million to $729.59 Million. Read More

Who are the leading companies in the US mycoplasma testing market?

Key players include Thermo Fisher Scientific, Merck KGaA, and F. Hoffmann-La Roche Ltd. Read More

What is the expected growth in the pharmaceutical companies segment of the US mycoplasma testing market?

The pharmaceutical companies segment is projected to grow from $186.76 Million to $610.0 Million. Read More

How does the biotechnology companies segment compare in growth to other segments?

The biotechnology companies segment is expected to grow from $139.8 Million to $450.0 Million, indicating robust growth. Read More

What role do academic research institutes play in the US mycoplasma testing market?

Academic research institutes are projected to grow from $137.63 Million to $469.59 Million, highlighting their importance. Read More

What trends are influencing the US mycoplasma testing market?

Trends include increased focus on quality control and research and development, with respective growth from $100.0 Million to $320.0 Million and $150.0 Million to $480.0 Million. Read More

US Mycoplasma Testing Market

ID: MRFR/LS/17265-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026

US Mycoplasma Testing Market Research Report By Test Type (PCR Testing, ELISA Testing, Culture Testing, Nucleic Acid Hybridization), By Application (Quality Control, Research and Development, Diagnostic Testing) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutes) - Growth & Industry Forecast 2025 To 2035

US Mycoplasma Testing Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)11.45%

2024 Market Size$ 464.19 Million

2025 Market Size$ 517.34 Million

2035 Market Size$ 1,529.59 Million

Key Players

Thermo Fisher Scientific

Merck KGaA

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories

Lonza Group AG

Gen-Probe

Trends

Technological Advancements in Testing Methods
Regulatory Compliance and Quality Assurance
Growing Demand in Biopharmaceuticals

Opportunities

Stringent Regulatory Frameworks
Advancements in Molecular Testing Techniques
Rising Prevalence of Mycoplasma Contamination

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Test Type (USD Million)
  1. 4.1.1 PCR Testing
  2. 4.1.2 ELISA Testing
  3. 4.1.3 Culture Testing
  4. 4.1.4 Nucleic Acid Hybridization
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 Quality Control
  2. 4.2.2 Research and Development
  3. 4.2.3 Diagnostic Testing
3. 4.3 Life Sciences, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Academic Research Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 F. Hoffmann-La Roche Ltd (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bio-Rad Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Lonza Group AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Gen-Probe (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Charles River Laboratories (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Norgen Biotek Corp (CA)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TEST TYPE
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
11. 6.11 LIFE SCIENCES, BY TEST TYPE, 2024 (% SHARE)
12. 6.12 LIFE SCIENCES, BY TEST TYPE, 2024 TO 2035 (USD Million)
13. 6.13 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
15. 6.15 LIFE SCIENCES, BY END USE, 2024 (% SHARE)
16. 6.16 LIFE SCIENCES, BY END USE, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Get Free Sample PDF

Certified Researchers

Customize Report

US Mycoplasma Testing Market Segmentation

US Mycoplasma Testing Market By Test Type (USD Million, 2025-2035)

PCR Testing
ELISA Testing
Culture Testing
Nucleic Acid Hybridization

US Mycoplasma Testing Market By Application (USD Million, 2025-2035)

Quality Control
Research and Development
Diagnostic Testing

US Mycoplasma Testing Market By End Use (USD Million, 2025-2035)

US Mycoplasma Testing Market Companies
Biotechnology Companies
Academic Research Institutes

Get Free Sample PDF

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”